The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Abstract
People with type 2 diabetes (T2d) are at high risk for adverse cardiovascular (cV) outcomes and progressive decline in renal function. In comparison with the general population, they are 2 to 4 times more likely to be hospitalised or to die from cV causes, including atherosclerotic cV disease (AScVd) and heart failure.1-3 Approximately one third of patients with T2d who develop heart failure have no history of prior coronary heart disease, and while careful control of modifiable cV risk factors can ameliorate risk of death, myocardial infarction (mI) and stroke, the incidence of heart failure in T2d remains consistently higher than that of matched controls.2,3 Therefore, prevention and treatment of these cV complications is fundamental to the management of T2d. Until recently, the primary requirement for trials of drug therapy for T2d has been to show glucose-lowering efficacy and safety. However, concerns over the cV safety of some more recently introduced antihyperglycaemic agents prompted the US Food and drug Administration (FdA) to mandate that from 2008 all new drugs should also be tested for cV safety.4 Furthermore, in the light of data from these cV outcomes trials, new 2018 recommendations for antihyperglycaemic therapy for adults with T2d include early incorporation of an agent proven to reduce major adverse cV events (mAce) and/or cV mortality.5 most cV outcomes trials have shown a neutral effect of antihyperglycaemic agents on cV events. However, well powered randomised controlled trials have demonstrated that the sodium-glucose co-transporter-2 (SGLT-2) inhibitors have favourable effects on cV and renal outcomes, which remain consistent across a broad range of patient subgroups.4,6-8 The most recent of these studies is the Dapagliflozin Effect on Cardiovascular Events Thrombolysis in Myocardial Infarction 58 (decLAreTImI 58) trial, which was designed to evaluate the effects of dapagliflozin on cV and renal outcomes in a broad population of patients with T2d, including those with or without AScVd.8 The results of decLAre-TImI 58, which are summarised in this article, were presented at the 2018 Scientific Sessions of the American Heart Association in November.9
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Acute kidney injury from SGLT2 inhibitors: potential mechanisms
Hahn, K. M., Ejaz, A. A., Kanbay, M., Lanaspa, M. A., & Johnson, R. J. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.159 · Cited by 133
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
Hicks, K. A., Tcheng, J. E., Bozkurt, B., CHAITMAN, B. R., Cutlip, D. E., Farb, A. A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., et al. (2015) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0209-1 · Cited by 69
Zinman, B., Åhrén, B., Neubacher, D., Patel, S. D., Woerle, H., & Johansen, O. E. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.06.010 · Cited by 33
Chakravarty, A., Rastogi, M., Dhankhar, P., & Bell, K. F. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1434182 · Cited by 29
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 19
Cited by
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-09
- Volume
- 380
- Issue
- 19
- Pages
- 1880-1882
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2980595514
- Cited by
- 290
- References
- 9
- FWCI
- 37.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. https://app.cochat.ai/papers/10.1056/nejmc1902837
- The paper
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. (2019). New England Journal of Medicine. https://doi.org/10.1056/nejmc1902837
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.